68Ga标记的SSR靶向多肽PET/CT显像的研究进展及其在神经内分泌肿瘤中的初步应用

Advances of 68Ga-labelled SSR-targeted peptides (DOTA-TOC,-TATE,-NOC) PET/CT imaging and its preliminary application in neuroendocrine tumors

    摘要
  • 摘要: 近年来,68Ga标记的多肽PET/CT显像为神经内分泌肿瘤(NET)的诊断提供了新的方法和视角。68Ge/68Ga发生器已经商业化,容易获得,并且68Ga标记过程简单方便,显像剂稳定性好。在此基础上,越来越多的研究比较了68Ga标记的多肽PET/CT与传统的形态学显像方法(CT、MRI)及生长抑素受体扫描对NET病灶的诊断效能,发现68Ga标记的多肽PET/CT远远优于后者。此外,68Ga标记的多肽PET/CT显像还能为患者治疗方案的选择、辐射剂量的调整甚至预后效果的评估提供多种重要信息,其有望成为NET患者肿瘤显像的临床首选。笔者就近年来68Ga标记的多肽PET/CT显像在临床上的初步应用研究作一综述。

     

    Abstract: In recent years, 68Ga-labelled peptides PET/CT has provided a new approach and perspective for the diagnosis of neuroendocrine tumors (NET). 68Ge/68Ga generator has been commercialized, with 68Ga obtained easily. The labeling process is easy, and the 68Ga-labelled peptides are stable.There are an increasing number of reports about the much better diagnostic performance of 68Ga-labelled peptides PET/CT for the detection of NET lesions as compared to traditional morphological imaging procedures (CT, MRI) and somatostatin receptor scintigraphy. In addition, it can offer important clinical information in selecting treatment plan, adjusting the radiation dose and assessing the prognosis. 68Ga-labelled peptides PET/CT is expected to be the standard method and first choice for imaging NET. An overview about the introduction and application of 68Ga-labelled peptides PET/CT in clinical practice is presented.

     

    • HTML全文
    • 参考文献(24)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回